Literature DB >> 19433560

Antiretroviral drug resistance surveillance among treatment-naive human immunodeficiency virus type 1-infected individuals in Angola: evidence for low level of transmitted drug resistance.

Inês Bártolo1, Cheila Rocha, José Bartolomeu, António Gama, Marlene Fonseca, Ana Mendes, Filipa Cristina, Sven Thamm, Marta Epalanga, Patrícia Cavaco Silva, Nuno Taveira.   

Abstract

The prevalence of transmitted human immunodeficiency virus type 1 drug resistance in Angola in 2001 in 196 untreated patients was investigated. All subtypes were detected, along with unclassifiable and complex recombinant strains. Numerous new polymorphisms were identified in the reverse transcriptase and protease. Two (1.6%) unrelated patients harbored nucleoside reverse transcriptase inhibitor- and nonnucleoside reverse transcriptase inhibitor-resistant viruses (mutations: M41L, D67N, M184V, L210W, T215Y or T215F, and K103N). Continued surveillance of drug resistance is required for maximization of ART efficacy in Angola.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19433560      PMCID: PMC2704687          DOI: 10.1128/AAC.00110-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.

Authors:  Robert W Shafer; Soo-Yon Rhee; Deenan Pillay; Veronica Miller; Paul Sandstrom; Jonathan M Schapiro; Daniel R Kuritzkes; Diane Bennett
Journal:  AIDS       Date:  2007-01-11       Impact factor: 4.177

2.  Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes.

Authors:  Marie Gueudin; Jean Christophe Plantier; Véronique Lemée; Marie Paule Schmitt; Loic Chartier; Thomas Bourlet; Annick Ruffault; Florence Damond; Muriel Vray; François Simon
Journal:  J Acquir Immune Defic Syndr       Date:  2007-04-15       Impact factor: 3.731

3.  The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.

Authors:  Charles F Gilks; Siobhan Crowley; René Ekpini; Sandy Gove; Jos Perriens; Yves Souteyrand; Don Sutherland; Marco Vitoria; Teguest Guerma; Kevin De Cock
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

Review 4.  Epidemiology of antiretroviral drug resistance in drug-naïve persons.

Authors:  Anna Maria Geretti
Journal:  Curr Opin Infect Dis       Date:  2007-02       Impact factor: 4.915

5.  Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.

Authors:  John D Baxter; Jonathan M Schapiro; Charles A B Boucher; Veronika M Kohlbrenner; David B Hall; Joseph R Scherer; Douglas L Mayers
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

6.  High genetic diversity of human immunodeficiency virus type 1 in Angola.

Authors:  Inês Bártolo; Marta Epalanga; José Bartolomeu; Marlene Fonseca; Ana Mendes; António Gama; Nuno Taveira
Journal:  AIDS Res Hum Retroviruses       Date:  2005-04       Impact factor: 2.205

7.  Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience.

Authors:  Anita Shet; Leslie Berry; Hiroshi Mohri; Saurabh Mehandru; Chris Chung; Alexandria Kim; Patrick Jean-Pierre; Christine Hogan; Viviana Simon; Daniel Boden; Martin Markowitz
Journal:  J Acquir Immune Defic Syndr       Date:  2006-04-01       Impact factor: 3.731

8.  Highly divergent subtypes and new recombinant forms prevail in the HIV/AIDS epidemic in Angola: new insights into the origins of the AIDS pandemic.

Authors:  Inês Bártolo; Cheila Rocha; José Bartolomeu; António Gama; Rute Marcelino; Marlene Fonseca; Ana Mendes; Marta Epalanga; Patrícia Cavaco Silva; Nuno Taveira
Journal:  Infect Genet Evol       Date:  2008-05-09       Impact factor: 3.342

9.  Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004.

Authors:  Visva Pillay; Johanna Ledwaba; Gillian Hunt; Mpho Rakgotho; Beverly Singh; Lindiwe Makubalo; Diane E Bennett; Adrian Puren; Lynn Morris
Journal:  Antivir Ther       Date:  2008

10.  Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.

Authors:  Eva Poveda; Carmen de Mendoza; Luz Martin-Carbonero; Angélica Corral; Verónica Briz; Juan González-Lahoz; Vincent Soriano
Journal:  J Antimicrob Chemother       Date:  2007-07-23       Impact factor: 5.790

View more
  10 in total

1.  Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.

Authors:  Eran Bendavid; Philip Grant; Annie Talbot; Douglas K Owens; Andrew Zolopa
Journal:  AIDS       Date:  2011-01-14       Impact factor: 4.177

2.  Low Rates of Transmitted Drug Resistance Among Newly Identified HIV-1 Seroconverters in Rural Rakai, Uganda.

Authors:  Steven J Reynolds; Victor Ssempijja; Ronald Galiwango; Anthony Ndyanabo; Gertrude Nakigozi; Fred Lyagoba; Jamirah Nazziwa; Andrew Redd; Susanna L Lamers; Ron Gray; Maria Wawer; David Serwadda; Thomas C Quinn
Journal:  AIDS Res Hum Retroviruses       Date:  2016-11-28       Impact factor: 2.205

Review 3.  The global status of HIV drug resistance: clinical and public-health approaches for detection, treatment and prevention.

Authors:  Steven Y Hong; Jean B Nachega; Karen Kelley; Silvia Bertagnolio; Vincent C Marconi; Michael R Jordan
Journal:  Infect Disord Drug Targets       Date:  2011-04

Review 4.  HIV treatment as prevention and HPTN 052.

Authors:  Myron S Cohen; Marybeth McCauley; Theresa R Gamble
Journal:  Curr Opin HIV AIDS       Date:  2012-03       Impact factor: 4.283

5.  Transmitted HIV drug resistance in treatment-naive Romanian patients.

Authors:  Aura Temereanca; Luminita Ene; Sanjay Mehta; Loredana Manolescu; Dan Duiculescu; Simona Ruta
Journal:  J Med Virol       Date:  2013-04-16       Impact factor: 2.327

6.  Rare HIV-1 Subtype J Genomes and a New H/U/CRF02_AG Recombinant Genome Suggests an Ancient Origin of HIV-1 in Angola.

Authors:  Inês Bártolo; Rita Calado; Pedro Borrego; Thomas Leitner; Nuno Taveira
Journal:  AIDS Res Hum Retroviruses       Date:  2016-06-01       Impact factor: 2.205

7.  HIV-1 diversity, transmission dynamics and primary drug resistance in Angola.

Authors:  Inês Bártolo; Suzana Zakovic; Francisco Martin; Claudia Palladino; Patrícia Carvalho; Ricardo Camacho; Sven Thamm; Sofia Clemente; Nuno Taveira
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

8.  Early infant diagnosis of HIV-1 infection in Luanda, Angola, using a new DNA PCR assay and dried blood spots.

Authors:  Francisco Martin; Claudia Palladino; Rita Mateus; Anna Bolzan; Perpétua Gomes; José Brito; Ana Patrícia Carvalho; Yolanda Cardoso; Cristovão Domingos; Vanda Sofia Lôa Clemente; Nuno Taveira
Journal:  PLoS One       Date:  2017-07-17       Impact factor: 3.240

9.  HIV-1 genetic diversity and transmitted drug resistance mutations among patients from the North, Central and South regions of Angola.

Authors:  Joana Morais Afonso; Gonzalo Bello; Monick L Guimarães; Marta Sojka; Mariza G Morgado
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

10.  An affordable HIV-1 drug resistance monitoring method for resource limited settings.

Authors:  Justen Manasa; Siva Danaviah; Sureshnee Pillay; Prevashinee Padayachee; Hloniphile Mthiyane; Charity Mkhize; Richard John Lessells; Christopher Seebregts; Tobias F Rinke de Wit; Johannes Viljoen; David Katzenstein; Tulio De Oliveira
Journal:  J Vis Exp       Date:  2014-03-30       Impact factor: 1.355

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.